Fubotv earnings beat by $0.10, revenue topped estimates
David Owens, Chief Medical (TASE:PMCN) Officer and Director at Nexalin Technology , Inc. (NASDAQ:NXL), recently acquired 1,000 shares of the company’s common stock. The purchase, executed on February 4, 2025, was made at a price of $2.98 per share, bringing the total transaction value to $2,980. The timing appears strategic, as InvestingPro data shows NXL has delivered an impressive 699% return over the past year, with the stock currently trading at $3.11. Following this acquisition, Owens now holds 154,793 shares directly. This transaction reflects Owens’ continued investment in Nexalin Technology, a company specializing in electromedical and electrotherapeutic apparatus. While the company maintains strong liquidity with a current ratio of 16.39 and more cash than debt, InvestingPro analysis indicates analysts don’t expect profitability this year. Discover 8 more exclusive insights about NXL with an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.